Appraisal in progress
Indication |
|
| Status: In progress | |
Pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in at‑risk men who have sex with men, including adolescents (with body weight at least 35 kg). |
|
Medicine details |
|
| Medicine name | emtricitabine/tenofovir alafenamide fumarate (Descovy®) |
| Formulation | 200 mg/25 mg film-coated tablet |
| Reference number | 2566 |
| Indication | as above |
| Company | Gilead Sciences Ltd |
| BNF chapter | Infections |
| Submission type | Directed |
| Status | In progress |
| NMG meeting date | 07/06/2023 |
| AWMSG meeting date | 11/07/2023 |
| Date of issue | TBC |